Search

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Outlook for Partnering in Animal Health 2024

Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Pets

New consortium EUbOPEN will provide tools to unlock disease biolog

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

Social Impact | COVID-19 | Boehringer Ingelheim US

Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.

PetPro Connect: Veterinary Medicine in the Digital Age

Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Patient Week 2024 demonstrates importance of #PatientPoweredProgress

Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.

Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

Results from Phase II MASH trial announced at EASL 2024

Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024

Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic

Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.

Shelter Revamps Make for Strong Bonds, More Adoptions

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

A legacy in the making: Working together to spark meaningful change

Discover Jim’s passion for being an advocate for meaningful causes.

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

The Burdens of Schizophrenia

It can be hard for people living without schizophrenia to realize its burdens. Understanding these challenges can provide insights to help patients in need.

Six creative Connecticut students turn aspiring ideas into inventive innovation

Learn about the 2023 Connecticut Invention Convention winners.

New Platform: Unbridle Your Potential | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

FDA accepts Jardiance sNDA for T2D in children 10 and older

Outlook for Partnering in Animal Health 2024

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Pets

New consortium EUbOPEN will provide tools to unlock disease biolog

S&P Animal Health Partnering Oct 2023

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

Social Impact | COVID-19 | Boehringer Ingelheim US

PetPro Connect: Veterinary Medicine in the Digital Age

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Patient Week 2024 demonstrates importance of #PatientPoweredProgress

Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

Results from Phase II MASH trial announced at EASL 2024

Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic

Shelter Revamps Make for Strong Bonds, More Adoptions

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

A legacy in the making: Working together to spark meaningful change

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

The Burdens of Schizophrenia

Six creative Connecticut students turn aspiring ideas into inventive innovation

New Platform: Unbridle Your Potential | Boehringer Ingelheim US

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial